Rank |
Status |
Study |
1 |
Not yet recruiting
|
The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults
Condition: |
Healthy Volunteers |
Interventions: |
Drug: Alendronate; Drug: Hepatitis B Vaccine; Drug: Placebo |
Outcome Measures: |
Safety/Adverse events; Efficacy |
|
2 |
Recruiting
|
Testosterone and Alendronate in Hypogonadal Men
Conditions: |
Hypogonadism; Osteopenia; Osteoporosis |
Interventions: |
Drug: Testosterone; Drug: Alendronate; Drug: Placebo Alendronate; Drug: Placebo Testosterone |
Outcome Measure: |
Spine Bone Mineral Density by DXA |
|
3 |
Unknown †
|
Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?
Condition: |
Peritoneal Dialysis |
Intervention: |
Drug: alendronate (Fosamax) |
Outcome Measures: |
1.Changes of calcification score of coronary arteries and aorta; 2.Changes of bone density; changes of parathyroid hormone; changes of serum calcium and phosphate level; changes of C reactive protein; changes of lipid profile; adverse reactions |
|
4 |
Unknown †
|
Fosamax for Childhood Cancer Survivors
Condition: |
Osteoporosis |
Interventions: |
Drug: Alendronate; Drug: Placebo |
Outcome Measures: |
The percent change in bone mineral density (BMD) at lumbar spine at 36-weeks in subjects who receive active and control treatments; Changes in BMD at femoral neck; Changes in biochemical markers of bone turnover; Occurrence of clinical bone-related symptoms at 12-weeks and end of this study |
|
5 |
Not yet recruiting
|
RA Denosumab on Bone Microstructure Study
Condition: |
Rheumatoid Arthritis |
Interventions: |
Drug: Denosumab; Drug: Alendronate |
Outcome Measures: |
Changes from baseline in bone volumetric density at distal radius at 6th month; Changes from baseline in trabecular bone microarchitecture at distal radius at 6th month; Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 6th month; Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 6th month; Changes from baseline in areal bone density at total hip at 6th month; Changes from baseline in areal bone density at lumbar spine at 6th month; Changes in areal bone density at distal radius at 6th month; Changes from baseline in bone volumetric density at distal radius at 3rd month; Changes from baseline in trabecular bone microarchitecture at distal radius at 3rd month; Changes from baseline in bone volumetric density at the 2nd metacarpal bone at 3rd month; Changes from baseline in trabecular bone microarchitecture at 2nd metacarpal bone at 3rd month; Changes from baseline in areal bone density at total hip at 3rd month; Changes from baseline in areal bone density at lumbar spine at 3rd month; Changes in areal bone density at distal radius at 3rd month |
|
6 |
Recruiting
|
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Condition: |
Postmenopausal Women With Osteoporosis |
Interventions: |
Drug: Romosozumab; Drug: Alendronate |
Outcome Measures: |
Incidence of clinical fracture; Incidence of new vertebral fracture; Incidence of fracture; Percent changes in DXA Bone Mineral Density from baseline to 12 months; Percent changes in DXA Bone Mineral Density from baseline to 24 months; Percent changes in DXA Bone Mineral Density from baseline to 36 months |
|
7 |
Not yet recruiting
|
Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Condition: |
HIV |
Intervention: |
Drug: alendronate/vitamin D |
Outcome Measures: |
Percentage changes in BMD at a) the lumbar spine and b) proximal femur; Feasibility; Acceptability; Safety/Tolerability; Adherence; Bone Biomarkers |
|
8 |
Not yet recruiting
|
Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
Condition: |
Calcific Aortic Stenosis |
Interventions: |
Drug: Denosumab; Drug: Alendronic Acid; Drug: Denosumab Placebo; Drug: Alendronic Acid Placebo |
Outcome Measures: |
Change in aortic valve calcium score; Change in aortic valve 18F-NaF uptake; Change in aortic-jet velocity; Change in thoracic aortic and coronary artery calcium score; Change in thoracic spine bone mineral density; Change in quality of life determined by Short Form 36 Questionnaire |
|
9 |
Recruiting
|
Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
Condition: |
Osteoporosis |
Interventions: |
Drug: Alendronate; Drug: Placebo |
Outcome Measures: |
Incidence of new osteoporotic fractures; Equivalence of deaths with and without continued bisphosphonate therapy; Incidence of the combination of fractures and deaths |
|
10 |
Recruiting
|
Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly
Condition: |
Alveolar Bone Healing After Dental Extraction |
Intervention: |
Procedure: Dental extraction |
Outcome Measures: |
Alveolar socket filled by new bone; Mucosal injury |
|
11 |
Unknown †
|
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Condition: |
Osteoporosis |
Intervention: |
Drug: Alendronate |
Outcome Measure: |
|
|
12 |
Unknown †
|
Osteoporosis and Dental Implant
Condition: |
Osteoporosis |
Interventions: |
Drug: alendronate once weekly 70mg; Drug: placebo |
Outcome Measure: |
Dental CT |
|
13 |
Unknown †
|
Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
Conditions: |
Osteoporosis; Cystic Fibrosis |
Interventions: |
Drug: alendronate sodium; Drug: calcium carbonate; Drug: cholecalciferol |
Outcome Measure: |
|
|
14 |
Unknown †
|
Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
Conditions: |
Gaucher's Disease; Osteopenia |
Interventions: |
Drug: alendronate sodium; Drug: calcium carbonate; Drug: cholecalciferol |
Outcome Measure: |
|
|
15 |
Unknown †
|
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
Condition: |
Osteoporosis |
Intervention: |
Drug: Maxmarvil® |
Outcome Measure: |
analysis of Alendronate concentrate |
|
16 |
Recruiting
|
Stem Cell Recruitment in Osteoporosis Therapy
Condition: |
Low Bone Density |
Interventions: |
Drug: Teriparatide; Drug: Alendronate; Dietary Supplement: calcium and vitamin D |
Outcome Measures: |
Number of Stro-1+ MSCs at bone resorption sites in bone biopsies of subjects treated with PTH or ALN.; Number of p-Smad 2/3+ cells/mm2 at active resorption sites on bone biopsy specimens of subjects treated with PTH or ALN.; The percent increase in Stro-1+/CD146+ cells in the blood before and after treatment with PTH or ALN.; Number of human Stro-1+ MSCs at bone resorption sites in bone of Rag2-/- mice reconstituted with human bone marrow derived from subjects treated with PTH or ALN. |
|
17 |
Recruiting
|
Twenty Four Month Extension Study of BA058-05-003
Condition: |
Postmenopausal Osteoporosis |
Intervention: |
Drug: Alendronate |
Outcome Measures: |
Safety; Vertebral Fracture Incidence; Non-vertebral Fracture Incidence |
|
18 |
Recruiting
|
Bisphosphonate Biomarker Study
Conditions: |
Osteoporosis, With or Without Treatment; Bisphosphonate Treatment; Atypical Femur Fracture; Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ); Healthy Volunteers |
Intervention: |
|
Outcome Measures: |
Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups; Differential expression of miRNA biomarkers across participant groups within the study |
|
19 |
Recruiting
|
Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
Condition: |
Osteoporosis |
Intervention: |
Drug: Alendronate |
Outcome Measures: |
Clinical site recruitment rate; Participant recruitment rate; Contracting and procedures; Administrative procedures; Osteonecrosis of the jaw; Atypical femoral fracture; Clinical fracture rate |
|
20 |
Recruiting
|
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Condition: |
Postmenopausal Osteoporosis |
Intervention: |
Drug: Teriparatide 40-mcg subcutaneous injection |
Outcome Measure: |
Bone turnover marker (blood sample) |
|